A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.
about
Cancer microRNAs: from subtype profiling to predictors of response to therapyLet-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysisSNPing cancer in the bud: microRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancerNon-coding RNAs as theranostics in human cancersMicroRNAs in stress signaling and human diseaseA Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanomaA KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancerRETRACTED: Gene-gene interaction network analysis of ovarian cancer using TCGA dataThe KRAS-variant is associated with risk of developing double primary breast and ovarian cancerNo clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.SNPs in microRNA binding sites as prognostic and predictive cancer biomarkersPrevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families.MicroRNA binding site polymorphisms as biomarkers in cancer management and research.A polymorphism in a let-7 microRNA binding site of KRAS in women with endometriosis.The involvement of Kras gene 3'-UTR polymorphisms in risk of cancer and influence on patient response to anti-EGFR therapy in metastatic colorectal cancer: a meta-analysis.A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.MicroRNA signatures differentiate melanoma subtypes.KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study.Functional SNP in the microRNA-367 binding site in the 3'UTR of the calcium channel ryanodine receptor gene 3 (RYR3) affects breast cancer risk and calcification.Selective targeting of KRAS-mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-mutant cellsLet-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximabThe impact of 3'UTR variants on differential expression of candidate cancer susceptibility genes.MicroRNA-mediated regulation of KRAS in cancerThe role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testingActivation of KRAS promotes the mesenchymal features of basal-type breast cancer.Shielding the messenger (RNA): microRNA-based anticancer therapies.Targeted resequencing of the microRNAome and 3'UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancer.The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905MicroRNA processing and binding site polymorphisms are not replicated in the Ovarian Cancer Association Consortium.Targets of miR-200c mediate suppression of cell motility and anoikis resistanceMicroRNA 135 regulates HOXA10 expression in endometriosis.RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally.Evaluation of KRAS Gene Expression and LCS6 Variant in Genomic and Cell-Free DNA of Iranian Women With Endometriosis.MicroRNA genes and their target 3'-untranslated regions are infrequently somatically mutated in ovarian cancersMicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancerSingle-nucleotide polymorphism in microRNA-binding site of SULF1 target gene as a protective factor against the susceptibility to breast cancer: a case-control study.Estrogen withdrawal, increased breast cancer risk and the KRAS-variant.Childhood cancer: an emerging public health issue in China.A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysisSomamiR: a database for somatic mutations impacting microRNA function in cancer.
P2860
Q24594739-18AEFF94-B20A-496C-9104-B07FEF0C7DE3Q26827474-7B4F3DF0-ADA9-4959-AE5D-474D0AEB62DBQ26829794-EAD4AAD7-E655-4EDD-BC8B-CA02DB20BDBBQ26851250-6D19F45F-AE87-40E7-BE31-A48A3A89CFFCQ27027517-B93FAFCD-7D95-4156-AEB5-BF0AE4A2C4CFQ27851611-4C098AEC-A12F-40BC-B9E0-FBC816E1C449Q27851690-856CC51B-8B41-495E-9C92-040CA95213ABQ28386402-74E42EFD-63F2-434A-BFDF-D30D6ED57BE1Q28729202-72572107-5E8E-4412-B2C4-B6F38226E38AQ30374367-582E85EC-18D4-4926-BC91-8E5201D46BD6Q33640984-3F1AD88B-141C-4DE4-92F7-68BCB24A13E2Q33646928-6B792B80-199A-4853-95A2-856C9B014493Q34019040-CE548540-5FCA-4156-BC6B-B7F18DDF2A97Q34030553-41B60C2D-C085-4555-943A-C5AE09F42114Q34134870-0852D9D2-FEBB-4A7B-BD27-3A2DE4F3ED09Q34138308-4482B186-44C3-4C8A-9838-9BCB0AF8378FQ34182764-904121A2-B04F-48E9-B9FC-383725734BA8Q34205192-2AD6CED9-C34C-47D9-B1CA-7089F21E4BE3Q34205590-3A4B3798-8AA3-4B2C-9D70-54CB3E2B6C84Q34365804-4CF41CFC-6902-4C49-82D9-629CA33E2F2DQ34483581-64549C78-89BF-4361-8FC6-337C6D5CFF5BQ34615065-50C71CD0-7EE0-4FF0-ADEB-4F0133CBB730Q34678120-82B9858B-FE2F-426B-B831-CDD3349BFDDBQ35024008-C5C26CA4-4F89-465D-BC89-537A77BFEF26Q35040663-585A0A14-F6AF-42B5-B074-80A2115803FEQ35070602-71B5AAAE-8BD0-4B53-9C60-2A14D29B4635Q35079572-2DB2231C-9545-47CE-9E0C-76202D95B002Q35147597-F8795CEA-C444-4F6A-9E3C-C553E2E46F4DQ35156802-4BE56AC2-14B9-463D-BCD1-278D7B984B76Q35559037-E859A972-D7D9-4385-8BF0-C6889AF924B4Q35597918-852BF8A2-F5DE-4966-BB54-88C3C59211BDQ35683647-94FC47D0-39DC-40F9-9D78-41CDC233CC2EQ35853140-DF687148-B86F-4EA6-8C83-E0E0391A943DQ35908632-806A22E3-4D14-494D-8386-27E1DA7B9458Q36032709-C4C1404A-DF9D-400D-A805-3923FF799692Q36044425-02756805-C4EE-4269-9834-97D57101CF61Q36187913-8A8405C9-76D4-4DBC-B32D-B0A660A6DDA7Q36204952-EA0FCF95-D12C-4D41-ABA5-5A276AC91DBCQ36369415-BE361BF1-5042-4669-B4A4-5821621D6FE7Q36491386-F0DC5316-B9B0-4647-8F12-FE5EA474F1AE
P2860
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.
@ast
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.
@en
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.
@nl
type
label
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.
@ast
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.
@en
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.
@nl
prefLabel
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.
@ast
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.
@en
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.
@nl
P2093
P2860
P1433
P1476
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.
@en
P2093
Alessandro Santin
Andrew K Godwin
Cory Pelletier
Daniel Zelterman
Elena Ratner
Ellen Matloff
Harvey Risch
Herbert Yu
Lena J Chin
Lingeng Lu
P2860
P304
P356
10.1158/0008-5472.CAN-10-0689
P407
P577
2010-07-20T00:00:00Z